Skip to content
The Journal

Longevity, honestly/Compounds

Semax Just Got a Hall Pass. Your Brain Still Wants a Walk.

Washington just cleared the way for pharmacies to make the "brain peptide" Semax. That's a permission slip, not a report card. Here's what actually has data for a sharper brain as you age.

Human clinical trialEarly lab / animal researchRegulatory context3 min

Inspired Labs Editorial/Oct 29, 2026/8 sources

Semax Just Got a Hall Pass. Your Brain Still Wants a Walk.

Want a brain upgrade with actual data behind it? Go for a brisk walk. One workout nudges up BDNF, a growth factor your brain uses to build connections, and a regular habit nudges it more.

That's the free version. This week, the paid version got some big news.

On Oct 28, the US Department of Health and Human Services said it won't go after licensed pharmacies that compound six popular peptides while FDA writes the rules. One of them is Semax, the nasal-spray "brain peptide" the longevity internet loves.

So let's talk about your brain, and about what that announcement does and doesn't mean.

What does a sharper aging brain actually run on?

The best recent answer comes from a big US trial called POINTER. Researchers enrolled 2,111 adults aged 60 to 79 who sat a lot, ate so-so, and had other risk factors for memory decline.

Everyone got encouragement to live healthier. Half got a structured program with coaching and check-ins. After two years, thinking scores rose in both groups, and a little more in the structured one.

The gap was modest, and the researchers say they're still working out how much it matters day to day. But the recipe is refreshingly boring:

Move. Regular cardio, plus some strength and stretching work.

Eat like the MIND diet. Leafy greens, berries, nuts, beans, whole grains, olive oil, and fish, with less sugar and fried stuff.

Keep your brain busy, with company. Puzzles and brain games count, and so do clubs, classes, and friends.

Know your numbers. Blood pressure, weight, and lab results got regular check-ins in the structured group.

Notice what's not on the list: anything you sniff.

So what is Semax?

It's a short lab-made peptide, seven amino acids long, built from a fragment of a stress hormone called ACTH. Scientists in Russia designed it decades ago, and Russia registered it as nasal drops.

Its claim to fame is BDNF, that same brain growth factor. In a 2006 rat study, one nasal dose raised BDNF in the memory center of the brain by about 40%, and the rats did better on a learning task.

That's a real finding. It's also a rat finding.

Has anyone tested it on human brains?

A little, and mostly in Russia. When FDA reviewers combed the literature this summer, they found a handful of small studies, often in meeting abstracts with missing details.

In healthy people, the list is short. A 1996 study looked at 19 healthy men. A 2018 brain-scan study gave 24 healthy volunteers Semax or a dummy spray. Their brain-network patterns shifted within 20 minutes, but nobody tested whether their memory got any better.

FDA also found no published studies on how Semax moves through the human body, which is pretty basic homework for a drug. Reviewers flagged a possible anti-clotting effect from one paper as a bleeding concern worth taking seriously.

Wait, didn't the government just approve it?

No, and this is where people are going to get confused.

Here's the timeline. Before a July meeting, FDA staff recommended keeping Semax off the pharmacy compounding list. At that meeting, FDA's outside advisory panel voted 8 to 5 to add it anyway. On Oct 28, HHS said it won't take enforcement action against licensed pharmacies that compound nasal Semax with a prescription while FDA runs the formal rulemaking.

A hall pass lets you into the hallway. It doesn't mean you aced the test.

That's what this is. HHS's own notice says compounded drugs aren't FDA-approved, and the policy isn't binding and can be pulled if safety problems show up. Legal summaries of the policy also note it doesn't cover products sold as research chemicals.

None of the new paperwork contains a new study. The evidence for Semax on Oct 28 was the same as on Oct 27. Literature, not lore.

So is Semax a dud?

Not necessarily. The rat BDNF work is genuinely interesting, and a growth factor that helps brains wire up is a reasonable thing to study.

But nobody has run the trial that matters to you: a big, well-controlled study in healthy adults that measures memory and daily function over months. Until someone does, Semax is a promising rat story with a passport stamp.

If you remember one thing…

A hall pass isn't a report card. The brain habits with real human trial data come with sneakers, a salad, and a friend, and you can start them this afternoon.

Everything Inspired Labs carries is for Research Use Only. It's lab material, not for your body, and nothing here is medical advice.

Sources

  1. 01Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial — Baker LD, Espeland MA, Whitmer RA, et al (2025). JAMA.

    Human-rct (2,111 adults aged 60–79 at risk of cognitive decline; 2 years; global cognition improved in both arms, more with the structured program; authors say clinical significance and longer-term effects need further study). Habit details from the Alzheimer's Association study-results page: https://www.alz.org/us-pointer/study-results

  2. 02A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor — Szuhany KL, Bugatti M, Otto MW (2015). J Psychiatr Res.

    Meta-analysis (29 human studies, about 1,100 people; moderate BDNF rise after a single session, larger after regular training, small rise in resting levels; smaller effects in studies with more women).

  3. 03Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Dolotov OV, Karpenko EA, Inozemtseva LS, et al (2006). Brain Res.

    Preclinical (single intranasal dose; hippocampal BDNF protein up to 1.4-fold; more conditioned avoidance responses).

  4. 04Effects of Semax on the default mode network of the brain — Lebedeva IS, Panikratova YR, Sokolov OY, et al (2018). Bull Exp Biol Med.

    Small human placebo-controlled imaging study (24 healthy volunteers: 14 Semax, 10 placebo; resting-state fMRI before and 5 and 20 minutes after; network topography changed; no cognitive outcome reported in the abstract; randomization not described).

  5. 05Semax-related bulk drug substances: Semax (free base) and Semax acetate — U.S. Food and Drug Administration (2026). Pharmacy Compounding Advisory Committee presentation, July 24, 2026.

    Regulatory (FDA proposed NOT adding either form to the 503A bulks list; not well characterized; insufficient effectiveness evidence for cerebral ischemia, migraine, trigeminal neuralgia; no published human PK studies; possible anti-thrombotic property raises bleeding concern; immunogenicity concern; registered drug in Russia as nasal drops; human safety table lists Kaplan 1996, 19 healthy adult males).

  6. 06"FDA advisory panel recommends peptide Semax be added to pharmacy compounding list." Jul 24, 2026 — Reuters, via Yahoo News (2026). Reuters, via Yahoo News.

    Regulatory news (8 for, 5 against, 1 abstention; FDA not bound by the panel).

  7. 07Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances — U.S. Department of Health and Human Services (2026). Notice of availability, Docket HHS-OASH-2026-0496, FR Doc.

    Regulatory (HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding listed peptides while the 503A list is developed through rulemaking; compounded drugs are not FDA-approved; policy not binding and may be revisited for safety signals or quality issues; 2-week comment period).

  8. 08"HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Oct 28, 2026 — BakerHostetler (2026). BakerHostetler.

    Legal summary (six peptides: BPC-157, TB-500, Epitalon, Semax, KPV, MOTS-c; Semax free base, intranasal only; patient-specific prescription; single active ingredient; policy is not FDA approval and does not apply to 503B outsourcing facilities or to products sold as research chemicals or dietary supplements).

Educational material for laboratory research context only. Nothing here is medical advice, a protocol for human use, or a claim that Inspired Labs products diagnose, treat, cure, or prevent disease.

Inspired Labs — Precision. Purity. Performance.